Interest in carbohydrate antigens grows with Siamab acquisition

Siamab's acquisition by an undisclosed pharma is the latest example of pharma's growing interest in targeting sugar groups to treat cancer. The announcement comes less than two years after the biotech teamed up with Boehringer to go after carbohydrate antigens.

Siamab Therapeutics

Read the full 412 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE